April 20, 2024 3:49 am
Cartherics and TiCARos collaborate to lead advancement of CLIP-CAR technology

Cartherics and TiCARos have formed a collaboration to develop CAR-NK products that can improve cancer therapies. TiCARos specializes in developing CLIP-CAR technology for the treatment of solid and blood cancers. This approach modifies the CAR structure to stabilize the immune synapse between immune cells and target tumor cells, resulting in improved efficacy in models.

Cartherics CEO, Professor Alan Trounson, believes that combining TiCARos’ CLIP-CAR technology with Cartherics’ allogeneic NK cell platform has great potential to enhance cancer therapies. By collaborating with innovative companies like TiCARos, Cartherics aims to build a leading portfolio of therapeutic products for cancer treatment. The two companies are currently working on developing a CAR-NK product targeting tissue factor (TF) for triple negative breast cancer and other challenging cancers.

Each company has nominated a specific tumor antigen to target with the CARs, with Cartherics focusing on TF and TiCARos targeting CD19. The collaboration between the two companies aims to accelerate pipeline programs and expand the use of TiCARos’ technology beyond autologous cell therapies. If successful, Cartherics and TiCARos will negotiate a development and commercialization agreement for their CAR-NK therapeutic approach.

TiCARos is excited about this collaboration as it allows them to further develop their CLIP-CAR technology while also expanding their reach beyond autologous cell therapies. This partnership with Cartherics will help them bring new treatments to market faster while also improving the effectiveness of existing ones.

Overall, this collaboration between two innovative companies shows promise in advancing the field of immunotherapy for cancer treatment.

Leave a Reply